April 29th, 2021 at the following time:
1:00 - 5:00 pm Eastern Time

Dioptragen Therapeutics

Dioptragen Therapeutics is a start-up drug development company targeting myopia (nearsightedness). Dioptragen uses its proprietary pharmacogenomics platform to identify and test novel drug compounds that suppress myopia. Dioptragen has completed initial pre-clinical studies of the top 6 drugs identified by the platform, which demonstrated their high efficacy. The goal of the company is to develop anti-myopia eye drops and other ophthalmic formulations to prevent and suppress myopia development in children and young adults.

Myopia will affect 5 billion people by 2050. Almost 1 billion people will have high myopia and be at risk of blindness due to retinal detachment and myopic macular degeneration (MMD). Current treatment options for myopia are limited and cannot stop progression of myopia or prevent pathological (often blinding) complications associated with the disease. Current market for myopia control is 25% of the world population or 1.9 billion people and estimated to be ~$30 billion a year.

Euclid Vision Systems

Euclid Systems Corporation is a world leader in myopia management and manufacturer of advanced orthokeratology lens products. With headquarters in Virginia, USA, and offices in Shanghai and Beijing, China, Euclid is leading the efforts in myopia management across the globe.
Multiple clinical studies worldwide by prestigious independent researchers have proven the effectiveness of orthokeratology, and specifically the Euclid Emerald™ lens, on slowing the progression of myopia. The Euclid Ortho-K treatment has a unique, empirically fit lens design with no trial lenses required. Manufactured in the U.S., the Euclid lens design has received FDA approval in the U.S., CE mark for Europe, as well as regulatory approvals from numerous countries around the world. To learn more, visit www.euclidsys.com.

iVeena Delivery Systems

iVeena Delivery Systems, Inc. (iVeena) is a privately held, clinical stage biopharmaceutical company focusing on expanding its platform technology for non-invasive, pharmacologic corneal flattening to develop products that address unmet medical needs in ophthalmology.

The company’s lead program is IVMED-80, a novel treatment for keratoconus. iVeena is also developing IVMED-85 and IVMED-95 for the treatment of pediatric high myopia and adult low myopia respectively.

Kubota Vision

Kubota Vision is a clinical-stage biotech company focused on combining scientific innovations and cutting edge technology to develop modern ophthalmology solutions.


NovaSight is an Israeli eye care startup, developing revolutionary solutions for the assessment and treatment of early vision disorders, using advanced eye-tracking and AI technology.

Aiming to prevent pediatric vision loss, our products are specially designed for the unique needs and attention spans of children, focused on children’s diseases such as myopia and amblyopia.

NovaSight’s management and advisory boards is comprised of experienced executives and world-renowned experts bringing broad and multidisciplinary expertise in the field of vision care.

Reopia Optics

Nearsightedness, or myopia, is exploding around the world. Unless the trend is stopped, 50% of the world’s population will be myopic by the year 2050. Ten percent of these myopes will be at high risk for blinding complications.

It has recently been understood that the environment has a major impact on myopia progression. Over the past 20 years, the pattern of children’s play time has changed drastically. In the past, children played outdoors for hours, whereas today they spend hours each day on smart phones and other digital display devices (whether indoors or outdoors). Reopia Optics is developing patented eyeglasses that will prevent the myopia pandemic.

SightGlass Vision

SightGlass Vision, Inc. is a late-stage clinical / pre-commercial life sciences company focused on ending nearsightedness (myopia).


Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.